Tekla Accounts Payable vs Non Current Assets Total Analysis

HQL Stock

USD 14.13 0.21 1.51%

Tekla Life financial indicator trend analysis is much more than just breaking down Tekla Life Sciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tekla Life Sciences is a good investment. Please check the relationship between Tekla Life Accounts Payable and its Non Current Assets Total accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.

Accounts Payable vs Non Current Assets Total

Accounts Payable vs Non Current Assets Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tekla Life Sciences Accounts Payable account and Non Current Assets Total. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Tekla Life's Accounts Payable and Non Current Assets Total is 0.5. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of Tekla Life Sciences, assuming nothing else is changed. The correlation between historical values of Tekla Life's Accounts Payable and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Tekla Life Sciences are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Accounts Payable i.e., Tekla Life's Accounts Payable and Non Current Assets Total go up and down completely randomly.

Correlation Coefficient

0.5

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Tekla Life obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Tekla Life Sciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Most indicators from Tekla Life's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tekla Life Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.

At this time, Tekla Life's Enterprise Value Over EBITDA is quite stable compared to the past year. Enterprise Value Multiple is expected to rise to 14.12 this year, although the value of Selling General Administrative will most likely fall to about 692 K.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	1.4M	1.2M	1.3M	861.3K
Cost Of Revenue	5.5M	5.2M	6.0M	3.9M

Total Operating Expenses Cost Of Revenue

Tekla Life fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Total Liab	Total Current Assets	Common Stock	Net Receivables	Other Stockholder Equity	Net Tangible Assets	Retained Earnings	Long Term Investments	Other Liab	Other Current Assets	Short Term Investments	Capital Stock	Non Current Liabilities Total
Total Assets		0.17	0.51	1.0	0.3	0.5	-0.22	1.0	-0.96	-0.7	0.05	0.08	0.81	0.33	0.2	0.08	0.2	0.29	0.75	0.15	0.73	0.7	0.1	0.24	-0.33	0.18
Other Current Liab	0.17		0.26	0.16	0.31	-0.23	-0.11	0.17	-0.22	0.07	-0.51	0.01	-0.18	0.19	-0.31	0.01	-0.31	-0.15	0.36	0.51	0.39	-0.14	0.46	-0.18	0.07	0.76
Total Current Liabilities	0.51	0.26		0.49	0.01	0.71	0.18	0.52	-0.46	-0.25	0.27	-0.44	0.6	0.6	0.1	-0.44	0.11	0.61	0.34	-0.19	0.39	0.32	-0.2	0.68	-0.62	0.47
Total Stockholder Equity	1.0	0.16	0.49		0.31	0.49	-0.23	1.0	-0.96	-0.7	0.06	0.09	0.8	0.3	0.21	0.09	0.21	0.28	0.76	0.15	0.73	0.7	0.09	0.21	-0.31	0.15
Net Debt	0.3	0.31	0.01	0.31		0.33	-0.97	0.31	-0.33	-0.1	0.04	-0.45	0.17	-0.01	-0.26	-0.45	-0.23	0.38	0.38	0.26	0.4	0.07	0.16	0.01	-0.47	-0.11
Accounts Payable	0.5	-0.23	0.71	0.49	0.33		-0.28	0.5	-0.47	-0.33	0.65	-0.62	0.71	0.36	0.22	-0.62	0.24	0.87	0.31	-0.41	0.35	0.35	-0.45	0.71	-0.86	-0.16
Cash	-0.22	-0.11	0.18	-0.23	-0.97	-0.28		-0.23	0.24	0.08	-0.09	0.39	-0.13	0.13	0.21	0.39	0.18	-0.32	-0.28	-0.21	-0.29	-0.06	-0.12	0.06	0.39	0.31
Non Current Assets Total	1.0	0.17	0.52	1.0	0.31	0.5	-0.23		-0.96	-0.69	0.05	0.06	0.8	0.34	0.17	0.06	0.17	0.29	0.76	0.15	0.74	0.69	0.11	0.25	-0.33	0.18
Non Currrent Assets Other	-0.96	-0.22	-0.46	-0.96	-0.33	-0.47	0.24	-0.96		0.7	0.02	-0.1	-0.69	-0.37	-0.15	-0.1	-0.15	-0.25	-0.75	-0.19	-0.73	-0.57	-0.18	-0.2	0.3	-0.23
Other Assets	-0.7	0.07	-0.25	-0.7	-0.1	-0.33	0.08	-0.69	0.7		-0.15	-0.13	-0.68	-0.16	-0.21	-0.13	-0.21	-0.22	-0.78	-0.28	-0.74	-0.88	0.09	-0.22	0.22	0.03
Cash And Short Term Investments	0.05	-0.51	0.27	0.06	0.04	0.65	-0.09	0.05	0.02	-0.15		-0.58	0.43	-0.31	0.32	-0.58	0.33	0.75	0.05	-0.57	0.08	0.25	-0.89	0.39	-0.66	-0.65
Common Stock Total Equity	0.08	0.01	-0.44	0.09	-0.45	-0.62	0.39	0.06	-0.1	-0.13	-0.58		-0.22	-0.22	0.27	1.0	0.23	-0.88	0.01	0.37	-0.11	0.04	0.44	-0.64	0.89	0.1
Common Stock Shares Outstanding	0.81	-0.18	0.6	0.8	0.17	0.71	-0.13	0.8	-0.69	-0.68	0.43	-0.22		0.32	0.35	-0.22	0.35	0.59	0.51	-0.24	0.53	0.8	-0.36	0.61	-0.6	-0.09
Total Liab	0.33	0.19	0.6	0.3	-0.01	0.36	0.13	0.34	-0.37	-0.16	-0.31	-0.22	0.32		-0.17	-0.22	-0.17	0.28	0.11	-0.05	0.2	0.1	0.36	0.69	-0.34	0.68
Total Current Assets	0.2	-0.31	0.1	0.21	-0.26	0.22	0.21	0.17	-0.15	-0.21	0.32	0.27	0.35	-0.17		0.27	1.0	0.03	0.03	-0.19	-0.1	0.23	-0.3	-0.01	0.03	-0.29
Common Stock	0.08	0.01	-0.44	0.09	-0.45	-0.62	0.39	0.06	-0.1	-0.13	-0.58	1.0	-0.22	-0.22	0.27		0.23	-0.88	0.01	0.37	-0.11	0.04	0.44	-0.64	0.89	0.1
Net Receivables	0.2	-0.31	0.11	0.21	-0.23	0.24	0.18	0.17	-0.15	-0.21	0.33	0.23	0.35	-0.17	1.0	0.23		0.06	0.04	-0.16	-0.08	0.23	-0.29	-0.01	0.0	-0.3
Other Stockholder Equity	0.29	-0.15	0.61	0.28	0.38	0.87	-0.32	0.29	-0.25	-0.22	0.75	-0.88	0.59	0.28	0.03	-0.88	0.06		0.23	-0.47	0.33	0.28	-0.58	0.77	-0.99	-0.18
Net Tangible Assets	0.75	0.36	0.34	0.76	0.38	0.31	-0.28	0.76	-0.75	-0.78	0.05	0.01	0.51	0.11	0.03	0.01	0.04	0.23		0.46	0.97	0.71	0.15	0.0	-0.25	0.18
Retained Earnings	0.15	0.51	-0.19	0.15	0.26	-0.41	-0.21	0.15	-0.19	-0.28	-0.57	0.37	-0.24	-0.05	-0.19	0.37	-0.16	-0.47	0.46		0.38	0.16	0.6	-0.52	0.41	0.34
Long Term Investments	0.73	0.39	0.39	0.73	0.4	0.35	-0.29	0.74	-0.73	-0.74	0.08	-0.11	0.53	0.2	-0.1	-0.11	-0.08	0.33	0.97	0.38		0.67	0.11	0.13	-0.36	0.23
Other Liab	0.7	-0.14	0.32	0.7	0.07	0.35	-0.06	0.69	-0.57	-0.88	0.25	0.04	0.8	0.1	0.23	0.04	0.23	0.28	0.71	0.16	0.67		-0.2	0.27	-0.27	-0.1
Other Current Assets	0.1	0.46	-0.2	0.09	0.16	-0.45	-0.12	0.11	-0.18	0.09	-0.89	0.44	-0.36	0.36	-0.3	0.44	-0.29	-0.58	0.15	0.6	0.11	-0.2		-0.4	0.5	0.57
Short Term Investments	0.24	-0.18	0.68	0.21	0.01	0.71	0.06	0.25	-0.2	-0.22	0.39	-0.64	0.61	0.69	-0.01	-0.64	-0.01	0.77	0.0	-0.52	0.13	0.27	-0.4		-0.78	0.15
Capital Stock	-0.33	0.07	-0.62	-0.31	-0.47	-0.86	0.39	-0.33	0.3	0.22	-0.66	0.89	-0.6	-0.34	0.03	0.89	0.0	-0.99	-0.25	0.41	-0.36	-0.27	0.5	-0.78		0.12
Non Current Liabilities Total	0.18	0.76	0.47	0.15	-0.11	-0.16	0.31	0.18	-0.23	0.03	-0.65	0.1	-0.09	0.68	-0.29	0.1	-0.3	-0.18	0.18	0.34	0.23	-0.1	0.57	0.15	0.12

Click cells to compare fundamentals

Tekla Life Account Relationship Matchups

Tekla Life fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	484.2M	534.2M	414.7M	402.6M	463.0M	335.6M
Other Current Liab	(2.8M)	(12.1K)	10.7M	(5.1M)	(5.9M)	(5.6M)
Total Current Liabilities	2.8M	581.2K	10.7M	5.1M	5.9M	3.2M
Total Stockholder Equity	483.6M	523.4M	397.9M	401.9M	462.2M	332.0M
Net Debt	5.0M	1.3M	10.6K	(477.0)	(548.55)	(575.98)
Cash	(5.0M)	990.0	445.0	477.0	429.3	407.84
Non Current Assets Total	484.0M	534.0M	414.1M	397.5M	457.2M	332.8M
Non Currrent Assets Other	(484.0M)	(534.0M)	(414.1M)	(397.5M)	(357.8M)	(375.7M)
Other Assets	118.6K	33.0K	25.4K	26.3K	23.7K	22.5K
Cash And Short Term Investments	5.0M	990.0	445.0	15.2M	17.5M	18.4M
Common Stock Shares Outstanding	23.8M	24.3M	25.7M	26.8M	30.8M	19.2M
Liabilities And Stockholders Equity	484.2M	534.2M	414.7M	402.6M	463.0M	335.6M
Total Liab	595.2K	10.7M	16.8M	667.0K	767.0K	728.7K
Total Current Assets	73.9K	144.7K	623.9K	5.0M	5.8M	6.1M
Common Stock	238.8K	246.7K	256.8K	267.9K	308.1K	292.7K
Net Receivables	73.9K	150.3K	623.5K	5.0M	5.8M	6.1M
Other Stockholder Equity	356.3M	372.5M	388.1M	403.1M	463.6M	486.8M
Net Tangible Assets	383.7M	483.6M	523.4M	397.9M	457.6M	449.7M
Retained Earnings	127.0M	150.7M	9.5M	(1.5M)	(1.7M)	(1.6M)
Long Term Investments	484.0M	534.0M	414.1M	397.5M	457.2M	444.7M
Other Current Assets	5.0M	8.5M	11.1M	(35.5M)	(32.0M)	(30.4M)
Short Term Investments	5.0M	17.2M	32.9M	15.2M	17.5M	12.9M
Capital Stock	238.8K	246.7K	256.8K	267.9K	241.1K	229.1K
Non Current Liabilities Total	569.2K	9.4M	5.1M	667.0K	600.3K	570.3K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Tekla Life Sciences is a strong investment it is important to analyze Tekla Life's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tekla Life's future performance. For an informed investment choice regarding Tekla Stock, refer to the following important reports:

How To Invest In Tekla

Details

Is Tekla Stock a good investment?

Details

What is Tekla Life's Net Worth?

Details

Largest Asset Management & Custody Banks Companies

View

Largest Financial Services Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.

You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.425

Dividend Share

1.3

Earnings Share

1.34

Revenue Per Share

0.134

Quarterly Revenue Growth

0.07

The market value of Tekla Life Sciences is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Life's value that differs from its market value or its book value, called intrinsic value, which is Tekla Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Life's market value can be influenced by many factors that don't directly affect Tekla Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tekla Accounts Payable vs Non Current Assets Total Analysis

Accounts Payable vs Non Current Assets Total

Accounts Payable vs Non Current Assets Total Correlation Analysis

Correlation Coefficient

Accounts Payable

Non Current Assets Total

Tekla Life fundamental ratios Correlations

Tekla Life Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tekla Life fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Total Stockholder Equity
Common Stock	+ 1.0	Common Stock Total Equity
Net Receivables	+ 1.0	Total Current Assets
Long Term Investments	+ 0.97	Net Tangible Assets

Capital Stock	- 0.99	Other Stockholder Equity
Cash	- 0.97	Net Debt
Non Currrent Assets Other	- 0.96	Non Current Assets Total
Non Currrent Assets Other	- 0.96	Total Stockholder Equity
Non Currrent Assets Other	- 0.96	Total Assets
Other Current Assets	- 0.89	Cash And Short Term Investments